AccessibilityHelpAbout Us
Proteomics International Laboratories logo

Proteomics International Laboratories(ASX) PIQ

Market CapA$24.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-33%
5 Year-87%
1 Year-55%
1 Month-6%
A$0.15
-3.33%
-0.00Today
Proteomics International Laboratories last closing stock price
MetricPriceDate
Last closeAUD 0.152026-09-08
Proteomics International Laboratories stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.45%AUD 0.162026-09-01
1 month-6.45%AUD 0.162026-08-07
3 month+20.83%AUD 0.122026-06-10
Year to date-77.86%AUD 0.662025-12-31
1 year-54.69%AUD 0.322025-09-08
3 year-84.41%AUD 0.932023-09-08
5 year-87.17%AUD 1.132021-09-09
Since inception-33.33%AUD 0.232015-04-16

Proteomics International Laboratories Financials at a Glance

Market Cap

A$24.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$3.98M

Net Income (TTM)

-A$16.77M

EPS (TTM)

-A$0.06

P/E Ratio

-2.38

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Price

A$0.15

Volume

0

Open

A$0.15

Previous Close

A$0.15

Daily Range

A$0.15 - A$0.15

52-Week Range

A$0.10 - A$0.86

Estimated Earnings Date

Aug 31, 2026

PIQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Proteomics International Laboratories

Proteomics International Laboratories Ltd is a medical technology company specializing in proteomics, focusing on innovative diagnostic solutions. The company operates in multiple regions, including Australia, New Zealand, the United States, Europe, India, and Southeast Asia.

Products and Services
  • PromarkerD: A blood test predicting diabetic kidney disease
  • PromarkerEndo: Diagnostic test for endometriosis, completed clinical validation
  • OxiDx (2-tag): Diagnostic test for oxidative stress treatment, completed clinical validation
Growth Outlook
  • Recent collaborations with leading research institutions enhance product development
  • Expansion into new markets is anticipated to drive revenue growth
  • Ongoing clinical trials for multiple diagnostic tests indicate strong future potential
Financial Highlights
  • Recent quarterly revenue of AUD 357,440 shows a focus on growth despite challenges
  • Cash and cash equivalents of AUD 7.67 million provide operational stability
  • Current ratio of 3.22 indicates strong liquidity position
Proteomics International Laboratories Ltd is positioned in a growing sector with a focus on innovative diagnostic solutions. The company’s flagship product, PromarkerD, addresses a significant health issue, while ongoing development of additional diagnostic tests demonstrates a commitment to expanding its product portfolio. Recent financial data reflects challenges, yet the liquidity position remains strong, allowing for continued investment in research and development. The strategic collaborations with prominent research institutions further enhance the company's potential for growth and innovation in the medical technology landscape.
AI Generated • Aug 28, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

CEO

David N. Morris

Website

www.proteomics.com.au

Headquarters

Nedlands, WA 6009, AU

PIQ Financials

Key Financial Metrics (TTM)

Gross Margin

-1927.07%

Operating Margin

-2555.92%

Net Income Margin

-2009.67%

Return on Equity

-93.66%

Return on Capital

-193.68%

Return on Assets

-85.45%

Earnings Yield

-42.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$24.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

165.37M

Volume

0

Avg. Volume

368.88K

Financials (TTM)

Gross Profit

-A$7.80M

Operating Income

-A$20.12M

EBITDA

-A$18.68M

Operating Cash Flow

-A$11.81M

Capital Expenditure

-A$2.11M

Free Cash Flow

-A$13.93M

Cash & ST Invst.

A$7.67M

Total Debt

A$681.45K

Proteomics International Laboratories Performance Analysis

Proteomics International Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 730,340-51.0%
20242024-06-30AUD 892,14322.2%
20252025-06-30AUD 587,389-34.2%
20262026-06-30AUD 278,015-52.7%
Proteomics International Laboratories sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30390.7%
Q22024-12-31-68.5%
Q42025-06-30-85.3%
Q22025-12-31190.6%
Proteomics International Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.0512.5%
20242024-06-30AUD -0.05-4.3%
20252025-06-30AUD -0.0619.1%
20262026-06-30AUD -0.05-13.7%
Proteomics International Laboratories sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3032.6%
Q22024-12-31-44.9%
Q42025-06-30-1.7%
Q22025-12-31-20.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$357.44K

-34.0%

Gross Profit

-A$5.00M

-58.8%

Gross Margin

-14.00%

N/A

Market Cap

A$24.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$154.07K

N/A

Employees

161

N/A

Net Income

-A$6.03M

-60.6%

EBITDA

-A$6.18M

-71.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$7.67M

+54.3%

Total Debt

A$681.45K

+1369.1%

Accounts Receivable

A$221.22K

+664.4%

Inventory

A$0.00

N/A

Long Term Debt

A$454.34K

+4037.9%

Short Term Debt

A$227.11K

+541.4%

Return on Assets

-85.45%

N/A

Return on Invested Capital

-1.39%

N/A

Free Cash Flow

-A$3.01M

-75.5%

Operating Cash Flow

-A$950.22K

+28.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NSB.AXNeuroScientific Biopharmaceuticals Limited
A$0.06-1.59%
NOX.AXNoxopharm Limited
A$0.07-1.41%
RAD.AXRadiopharm Theranostics Limited
A$0.01-10.00%
CSX.AXCleanSpace Holdings Limited
A$0.43-2.30%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$104.47+0.09%
NVDANvidia
$225.73-0.02%
ATAIAtaiBeckley
$7.28-0.01%
NOKNokia
$10.65+0.06%

Questions About PIQ

What is the current price of Proteomics International Laboratories?

Proteomics International Laboratories is trading at A$0.15 per share.

What is the 52-week range for Proteomics International Laboratories?

Over the past 52 weeks, Proteomics International Laboratories has traded between A$0.10 and A$0.86.

How much debt does Proteomics International Laboratories have?

As of the most recent reporting period, Proteomics International Laboratories reported total debt of A$331.13K.

How much cash does Proteomics International Laboratories have on hand?

Proteomics International Laboratories reported A$3.50M in cash and cash equivalents in its most recent financial results.

What is Proteomics International Laboratories’s dividend yield?

Proteomics International Laboratories does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services